Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123010) titled 'Integration of Host Metabolome and Gut Microbiome for Predicting the Therapeutic Efficacy of Schizophrenia Drugs' on April 21.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: The Second People's Hospital of Yibin
Condition:
Schizophrenia
Intervention:
First-episode drug-naive schizophrenia patients (patient group):None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-05-01
Target Sample Size: First-episode drug-naive schizophrenia patients (patient group):100;Healthy controls:50;
Countries of Recruitment:
China
To know more, visit https://www....